Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A diagnostic test based on sequencing long-lived SARS-CoV-2–specific memory T cells provides a complement to antibody testing for determining previous exposure to SARS-CoV-2.
Microbiome companies are scrambling for a piece of the action as checkpoint inhibitors combined with fecal microbiome transplants enhance patient responses to immunotherapy.
As big pharma interest grows in bioelectronics medicine, Astellas swoops in for a startup developing wireless, grain-sized devices powered by ultrasound for CNS disease monitoring and intervention.
Following mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes.
The new drug not only is a boon for patients with spinal muscular atrophy, but also may spearhead the development of further chemical RNA modulators for a broad range of conditions.
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.